Ventripoint Diagnostics Stock Performance
| VPT Stock | CAD 0.19 0.02 11.76% |
VentriPoint Diagnostics holds a performance score of 11 on a scale of zero to a hundred. The entity has a beta of -0.86, which indicates possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning VentriPoint Diagnostics are expected to decrease slowly. On the other hand, during market turmoil, VentriPoint Diagnostics is expected to outperform it slightly. Use VentriPoint Diagnostics value at risk, as well as the relationship between the skewness and day median price , to analyze future returns on VentriPoint Diagnostics.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in VentriPoint Diagnostics are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, VentriPoint Diagnostics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:10 | Last Split Date 2015-12-07 |
1 | Ventripoint Updates Submission to U.S. Food and Drug Administration for its Next Generation, AI-powered Heart-scanning Technology - Marketscreener.com | 01/21/2025 |
2 | Ventripoint Closes Third Tranche of Convertible Debenture Offering - TipRanks | 02/10/2025 |
3 | Ventripoint Diagnostics Secures 500,000 in Private Placement - TipRanks | 03/21/2025 |
| Begin Period Cash Flow | 5.2 M | |
| Free Cash Flow | -3.8 M |
VentriPoint |
VentriPoint Diagnostics Relative Risk vs. Return Landscape
If you would invest 10.00 in VentriPoint Diagnostics on December 25, 2024 and sell it today you would earn a total of 9.00 from holding VentriPoint Diagnostics or generate 90.0% return on investment over 90 days. VentriPoint Diagnostics is currently producing 1.608% returns and takes up 11.4073% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than VentriPoint, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
VentriPoint Diagnostics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for VentriPoint Diagnostics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as VentriPoint Diagnostics, and traders can use it to determine the average amount a VentriPoint Diagnostics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.141
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | VPT | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 11.41 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.61 actual daily | 32 68% of assets have higher returns |
Risk-Adjusted Return
| 0.14 actual daily | 11 89% of assets perform better |
Based on monthly moving average VentriPoint Diagnostics is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of VentriPoint Diagnostics by adding it to a well-diversified portfolio.
VentriPoint Diagnostics Fundamentals Growth
VentriPoint Stock prices reflect investors' perceptions of the future prospects and financial health of VentriPoint Diagnostics, and VentriPoint Diagnostics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on VentriPoint Stock performance.
| Return On Equity | -29.73 | ||||
| Return On Asset | -1.72 | ||||
| Operating Margin | (18.51) % | ||||
| Current Valuation | 30.9 M | ||||
| Shares Outstanding | 159.82 M | ||||
| Price To Earning | 47.50 X | ||||
| Price To Book | 7.13 X | ||||
| Price To Sales | 216.49 X | ||||
| Revenue | 49.18 K | ||||
| Gross Profit | 136.55 K | ||||
| EBITDA | (4.86 M) | ||||
| Net Income | (4.87 M) | ||||
| Cash And Equivalents | 713.21 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 274.38 K | ||||
| Current Ratio | 0.56 X | ||||
| Book Value Per Share | (0.01) X | ||||
| Cash Flow From Operations | (3.8 M) | ||||
| Earnings Per Share | (0.03) X | ||||
| Market Capitalization | 29.57 M | ||||
| Total Asset | 1.88 M | ||||
| Retained Earnings | (53.49 M) | ||||
| Working Capital | 240.09 K | ||||
About VentriPoint Diagnostics Performance
Evaluating VentriPoint Diagnostics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if VentriPoint Diagnostics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if VentriPoint Diagnostics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 295.08 | 280.33 | |
| Return On Tangible Assets | (2.33) | (2.44) | |
| Return On Capital Employed | (11.65) | (11.07) | |
| Return On Assets | (2.33) | (2.44) | |
| Return On Equity | (29.53) | (28.06) |
Things to note about VentriPoint Diagnostics performance evaluation
Checking the ongoing alerts about VentriPoint Diagnostics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for VentriPoint Diagnostics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| VentriPoint Diagnostics is way too risky over 90 days horizon | |
| VentriPoint Diagnostics has some characteristics of a very speculative penny stock | |
| VentriPoint Diagnostics appears to be risky and price may revert if volatility continues | |
| VentriPoint Diagnostics has accumulated 274.38 K in total debt. VentriPoint Diagnostics has a current ratio of 0.55, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist VentriPoint Diagnostics until it has trouble settling it off, either with new capital or with free cash flow. So, VentriPoint Diagnostics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like VentriPoint Diagnostics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for VentriPoint to invest in growth at high rates of return. When we think about VentriPoint Diagnostics' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 49.18 K. Net Loss for the year was (4.87 M) with profit before overhead, payroll, taxes, and interest of 136.55 K. | |
| VentriPoint Diagnostics has accumulated about 713.21 K in cash with (3.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Latest headline from news.google.com: Ventripoint Diagnostics Secures 500,000 in Private Placement - TipRanks |
- Analyzing VentriPoint Diagnostics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether VentriPoint Diagnostics' stock is overvalued or undervalued compared to its peers.
- Examining VentriPoint Diagnostics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating VentriPoint Diagnostics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of VentriPoint Diagnostics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of VentriPoint Diagnostics' stock. These opinions can provide insight into VentriPoint Diagnostics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for VentriPoint Stock Analysis
When running VentriPoint Diagnostics' price analysis, check to measure VentriPoint Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VentriPoint Diagnostics is operating at the current time. Most of VentriPoint Diagnostics' value examination focuses on studying past and present price action to predict the probability of VentriPoint Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VentriPoint Diagnostics' price. Additionally, you may evaluate how the addition of VentriPoint Diagnostics to your portfolios can decrease your overall portfolio volatility.